

Richard Haynes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2959438/publications.pdf>

Version: 2024-02-01

86
papers

19,018
citations

136885

32
h-index

62565

80
g-index

99
all docs

99
docs citations

99
times ranked

31763
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
2	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1330.	3.8	1,855
3	Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. <i>New England Journal of Medicine</i> , 2014, 371, 203-212.	13.9	1,367
4	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040.	13.9	1,013
5	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1529-1539.	13.9	823
6	Lopinavirâ€“ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2020, 396, 1345-1352.	6.3	569
7	Effects of nâˆ³ Fatty Acid Supplements in Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1540-1550.	13.9	510
8	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12â€™064 survivors of myocardial infarction: a double-blind randomised trial. <i>Lancet, The</i> , 2010, 376, 1658-1669.	6.3	501
9	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
10	Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B₁₂ vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2486.	3.8	283
11	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology,the</i> , 2016, 4, 829-839.	5.5	234
12	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
13	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
14	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1825-1833.	3.0	142
15	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	3.0	140
16	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet, The</i> , 2014, 384, 1684-1690.	6.3	124
17	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , 2015, 16, 65.	0.8	82
18	Neprilysin inhibition in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 738-743.	0.4	80

#	ARTICLE	IF	CITATIONS
19	ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. <i>American Heart Journal</i> , 2018, 198, 135-144.	1.2	78
20	The role of lipoprotein (a) in chronic kidney disease. <i>Journal of Lipid Research</i> , 2018, 59, 577-585.	2.0	77
21	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 591-598.	2.1	74
22	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001696.	1.6	65
23	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
24	Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1317-1329.	0.4	58
25	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	2.1	57
26	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
27	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 35-47.	0.7	49
28	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 31-39.	2.1	42
29	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 546-552.	2.2	41
30	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 47-60.	2.2	41
31	Chronic kidney disease, heart failure and neprilysin inhibition. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 558-564.	0.4	39
32	Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 127-137.	3.0	39
33	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	2.9	36
34	Serum Free Light Chains and the Risk of ESRD and Death in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2829-2837.	2.2	35
35	Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events in Diabetes (ASCEND). <i>Trials</i> , 2016, 17, 286.	0.7	34
36	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. <i>EclinicalMedicine</i> , 2021, 41, 101163.	3.2	33

#	ARTICLE	IF	CITATIONS
37	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
38	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322.	1.3	30
39	Late presentation of patients with end-stage renal disease for renal replacement therapy—is it always avoidable?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3646-3651.	0.4	27
40	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. <i>European Heart Journal</i> , 2020, 41, 3336-3342.	1.0	27
41	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1794-1801.	2.2	22
42	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. <i>Transplantation Research</i> , 2013, 2, 7.	1.5	21
43	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , 2017, 103, 1880-1890.	1.2	21
44	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , 2018, 93, 1165-1174.	2.6	21
45	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19
46	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	2.1	19
47	Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2738-2748.	3.0	19
48	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) — results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434.	2.6	18
49	Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. <i>European Heart Journal</i> , 2022, 43, 2010-2019.	1.0	18
50	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. <i>JAMA Network Open</i> , 2019, 2, e190223.	2.8	16
51	Effects of Omega-3 Fatty Acid Supplements on Arrhythmias. <i>Circulation</i> , 2020, 141, 331-333.	1.6	15
52	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK. <i>JAMA Network Open</i> , 2021, 4, e2139748.	2.8	15
53	LIPIDS IN CHRONIC KIDNEY DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 27-33.	0.6	14
54	Survival after Starting Renal Replacement Treatment in Patients with Autosomal Dominant Polycystic Kidney Disease: A Single-Centre 40-Year Study. <i>Nephron Clinical Practice</i> , 2012, 120, c42-c47.	2.3	14

#	ARTICLE	IF	CITATIONS
55	Kidney disease trials for the 21st century: innovations in design and conduct. <i>Nature Reviews Nephrology</i> , 2020, 16, 173-185.	4.1	14
56	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
57	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2â€“Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. <i>Clinical Therapeutics</i> , 2019, 41, 1767-1777.	1.1	12
58	Myeloma Kidney: Improving Clinical Outcomes?. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 342-351.	0.6	11
59	PCSK9 inhibition: ready for prime time in CKD?. <i>Kidney International</i> , 2018, 93, 1267-1269.	2.6	11
60	Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal) Tj ETQq0 0 0 rgBT /Overlock 10 Tt	0.7	10
61	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , 2020, 44, 2256-2266.	1.6	9
62	TaleNepriylsin and Nepriylsin inhibition in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 123-130.	1.0	9
63	Dual blockade of the renin-angiotensin system: are two better than one?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3602-3607.	0.4	8
64	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 348-354.	0.9	8
65	Proteinuria. <i>BMJ: British Medical Journal</i> , 2006, 332, 284.	2.4	7
66	How the NHS research governance procedures could be modified to greatly strengthen clinical research. <i>Clinical Medicine</i> , 2010, 10, 127-129.	0.8	7
67	Niacin for Reduction of Cardiovascular Risk. <i>New England Journal of Medicine</i> , 2014, 371, 1940-1944.	13.9	7
68	Homocysteine, the kidney, and vascular disease. <i>BMJ, The</i> , 2012, 344, e3925-e3925.	3.0	6
69	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396.	0.4	6
70	Does serum phosphate predict death and ESRD in CKD patients?. <i>Nature Reviews Nephrology</i> , 2013, 9, 438-439.	4.1	5
71	Statins in chronic kidney disease: time to move on?. <i>Nature Reviews Nephrology</i> , 2015, 11, 262-263.	4.1	5
72	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5

#	ARTICLE	IF	CITATIONS
73	Aspirin for primary prevention of vascular disease in people with diabetes. <i>BMJ: British Medical Journal</i> , 2009, 339, b4596-b4596.	2.4	4
74	Alemtuzumab: right drug, right dose?*. <i>Transplant International</i> , 2011, 24, 1051-1052.	0.8	3
75	Investigating modifications to participant information materials to improve recruitment into a large randomized trial. <i>Trials</i> , 2019, 20, 681.	0.7	3
76	Tocilizumab in COVID-19 therapy: who benefits, and how? â€œ Authors' reply. <i>Lancet, The</i> , 2021, 398, 300.	6.3	3
77	Quiz Page September 2013. <i>American Journal of Kidney Diseases</i> , 2013, 62, A26-A29.	2.1	2
78	Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes. <i>Nature Reviews Nephrology</i> , 2009, 5, 126-127.	4.1	1
79	Screening for risk with albuminuria: should we start from here?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3463-3465.	0.4	1
80	Outcomes of Elderly Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Treated with Immunosuppressive Therapy. <i>Nephron</i> , 2016, 133, 223-231.	0.9	1
81	Niacin: old habits die hard. <i>Heart</i> , 2016, 102, 170-171.	1.2	1
82	Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 530-531.	2.0	0
83	Clinical trials of lipid-modifying agents: design considerations. <i>Clinical Lipidology</i> , 2011, 6, 109-116.	0.4	0
84	Alemtuzumab induction therapy in kidney transplantation â€œ Authors' reply. <i>Lancet, The</i> , 2015, 385, 771.	6.3	0
85	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. <i>Clinica Chimica Acta</i> , 2015, 439, 112-114.	0.5	0
86	Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1465-1468.	0.4	0